| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 125.29 Cr | 0.3% | 80.2% |
| Total Income | 126.96 Cr | 0.3% | 77.8% |
| Expenditure | 125.42 Cr | 2.9% | 69.1% |
| PBT | 1.54 Cr | 72.0% | 156.4% |
| Net Profit | 0.49 Cr | 89.6% | 120.1% |
| OPM | 2.45% | 2.93pp | 4.81pp |
| NPM | 0.39% | 3.31pp | 3.81pp |
| EPS | 0.10 | 90.0% | 81.1% |
Revenue beats, profit collapses—margin recovery unproven
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Revenue beat (125 Cr vs ~70 Cr baseline). QoQ profit down 90%. Prior guidance 'stronger bottom-line'—top-line hit, bottom-line missed sharply.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (80% YoY) and ₹618 Cr order backlog are structural positives, but Q1 PAT collapsed to ₹0.5 Cr (0.4% NPM) despite 80% scale—evidence of margin control breakdown. Management targets 7-8% EBITDA in '1-2 years,' but timeline is vague and near-term visibility poor. Penta and SAEL are strategic wins but unproven in profit contribution. Key risk: order realization delays (SAEL 6-8 mo, trading 1-1.5 yr) and margin recovery unsubstantiated.
₹125.3 Cr
Revenue · +80.2% YoY₹0.5 Cr
Reported PAT · +120.1% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Earnings quality
What changed since the last call
Order backlog quantified
Upgrade₹618 Cr backlog reported; SAEL ₹52 Cr win is new. Order inflow ₹283 Cr shows robust pipeline. Prior call did not size backlog.
Penta Automation acquired
NewStrategic automation play, ₹25 Cr baseline revenue, 25-30% growth expected over 2-3 years. Synergies claimed across divisions. Not discussed in prior call.
Profit guidance misfire
WithdrawnPrior call promised 'stronger bottom-line'—delivered Q1 shows PAT ₹0.5 Cr, down 89.6% QoQ. No formal retraction, but execution faltered.
EBITDA margin target
New7-8% EBITDA in '1-2 years' is forward guidance, but lacks specificity. Current delivered OPM 2.5% vs call's stated 4% EBITDA; large gap unreconciled.
The Q&A
Analyst Prashantkumar pressed hard on why 80% revenue growth did not translate to operating leverage—EBITDA only 4% vs NPM 0.4%, and prior-quarter baseline unknown. Management deflected to 'next 1-2 years' and blamed nascent acquisitions. CFO blamed rounding for segment discrepancies—not credible. Investors left unsatisfied on path to profitability. Tone: polite but evasive.
Penta integration — Shaishav Vora, Prudent Investments
AnsweredAutomation required across machine tools, textiles, air engineering. Penta provides robotics and automation lines. Expected 25-30% growth over 2-3 years.
Operating profit gap — Prashantkumar Uttamlal, Individual Investor
PartialCurrent 4-6% EBITDA. Target 7-8% in next 1-2 years via operational efficiency and acquisitions maturing. Nascent businesses need time.
Trading division income — Prashantkumar Uttamlal, Individual Investor
DodgedMix of two divisions. We'll share offline.
Quickmill outlook — Arpan Gandhi, A.G. Capital Investments
AnsweredDoing well with pending orders. Expanding to Gulf, Mexico, Egypt, South America. Large orders booked in Saudi Arabia.
SAEL order upside — Prashantkumar Uttamlal, Individual Investor
PartialSolar manufacturing space will grow. This order opens doors to big opportunities. Couple of big pipelines may fructify in 2-3 quarters, 100%.
Guidance
FY27 revenue +10% YoY growth (~₹138 Cr target)
Medium'Around 10% top-line growth over last year' per MD. ₹618 Cr backlog supports target, but geopolitical headwinds (Middle East, tariffs) and order lead times (1-1.5 yr) pose realization risk.
Target 7-8% EBITDA in next 1-2 years
LowVague timeline ('1-2 years'), no FY-specific target. Current delivered OPM 2.5%, call-stated EBITDA 4%. No bridge articulated; relies on Penta synergies and operational efficiency (unproven).
Capex in machine tools and solar plants (~₹180 Cr FY27 implied)
MediumMachine tool capex yielding 30% production increase (achieved). Solar plant phased; targeting revenue-neutral in 3-4 years post 3-yr finance cost. Specific annual capex not quantified for FY27.
Risks the call surfaced
Order realization delays
HighSAEL ₹52 Cr commissioning in 6-8 months; trading orders 1-1.5 years. Delays or project cancellations could derail FY27 10% growth guidance.
Margin recovery unproven
HighPAT ₹0.5 Cr (0.4% NPM) on ₹125 Cr revenue despite 80% growth. OPM 2.5% delivered vs 4% call-stated; NPM 0.4% vs implied 2%+ EBITDA. Finance/tax costs appear high. 7-8% EBITDA target in '1-2 years' lacks quantified bridge.
Geopolitical & macro headwinds
MediumMiddle East conflict, tariff escalation, supply chain disruptions cited. Raw material cost inflation (copper, steel) being partially absorbed; pass-through to customers ongoing. Margin compression if pass-through stalls.
Integration execution risk
MediumPenta (₹25 Cr baseline) and Bioconserve (one-year-old) are early-stage. 25-30% growth expected for Penta, but no breakeven or profit confirmation. Cross-divisional synergies (automation in textiles, machine tools) are theoretical, unquantified.
Competitive & pricing pressure
MediumTextile machinery has established competitors (VA Tech Wabag, Ion Exchange for ZLD systems). Batliboi's market position unclear. Trading division dependent on overseas principals' brand and reputation.
Management
Score 6/10. MD is articulate and addresses most questions directly. CFO provides segment detail but relies on 'rounding' to explain ₹2 Cr discrepancy—lacks precision. Evasive on trading commission specifics (deferred to offline follow-up). Revenue guidance beaten (80% growth). Profit guidance missed (PAT down 89.6% QoQ). Order book solid but cash conversion broken. Margin promises ('7-8% EBITDA in 1-2 years') lack timeline, quantified bridge, or track record.
1 · 6-8 months
SAEL solar pollution-control system commissioning (₹52 Cr order)
2 · 1-2 quarters
Defense/aerospace trading orders delivery (~₹102 Cr pipeline)
3 · 1-2 years
Penta synergies realized, EBITDA margin inflection to 7-8%
Key risk: order realization delays (SAEL 6-8 mo, trading 1-1.5 yr) and margin recovery unsubstantiated.
80% Revenue Growth, 90% Profit Collapse—Inside Batliboi's Q1 Breakdown
Revenue soared to ₹125 Cr and beat guidance, but net profit collapsed 89.6% quarter-on-quarter to just ₹0.5 Cr. A ₹2.6 Cr gap between operating profit and reported net profit reveals a finance/tax leakage that erases all operating leverage. The market's 4.5% day-1 sell-off was justified—until management quantifies the margin bridge, profit quality remains suspect.
₹125 Cr
+80.2% YoY, beat guidance
₹0.5 Cr
-89.6% QoQ collapse
₹3.1 Cr
delivered operating level
₹2.6 Cr
82% of operating profit erased
Batliboi posted a monster revenue print: ₹125 Cr in Q1 FY27, up 80% year-on-year, and it beat the company's own forward guidance. That headline should have been a win. Instead, the stock fell 4.5% on day 1 and the street pushed back hard on the call. Here's why: reported net profit was just ₹0.5 Cr—down 89.6% from the prior quarter—on a 0.4% net margin. The operating profit was ₹3.1 Cr (OPM 2.5%); the gap of ₹2.6 Cr suggests a finance/tax leakage so large it erases all operating leverage from 80% revenue growth. The debate is now whether this is a one-time miss or a structural break in profit conversion.
The ₹2.6 crore gap that explains the sell-off
Operating profit sits at 2.5% of revenue (₹3.1 Cr on ₹125 Cr sales). But reported net profit of ₹0.5 Cr implies finance costs, tax, and/or exceptional charges totalling ₹2.6 Cr—a jaw-dropping 82% of operating profit. On the call, management did not reconcile this gap. The company's finance costs are high (debt-laden balance sheet from acquisitions), tax liability is lumpy (timing of provisioning), and there is no disclosure of exceptional charges. Until management breaks this down, investors will assume the worst: that the margin structure is broken or masked by one-time items.
Today we are at let's say 4% of our EBITDA. Going forward in next two, three years, definitely any company would look at improving the EBITDA by having operational efficiency coming in and we are working towards that. We are looking at something around 7% to 8% in next 1 year or 2 years to reach that operating level.
What changed on this call
Three major shifts: Penta Automation was acquired, a ₹25 Cr baseline automation company targeted for 25–30% growth over 2–3 years, with synergies promised across machine tools, textiles, and air engineering divisions. The order backlog was quantified for the first time at ₹618 Cr, with ₹52 Cr in SAEL Industries (solar pollution-control) as a landmark win; prior calls did not size the backlog. Profit guidance implicitly missed: the prior call promised 'stronger bottom-line results' for FY27, but Q1 reported PAT of ₹0.5 Cr on ₹125 Cr revenue (0.4% NPM) contradicts that. EBITDA margin target is new and vague: management targets 7–8% EBITDA in 'next 1–2 years,' but does not specify fiscal year, provide a bridge, or quantify phased improvement.
₹125 Cr revenue, 80% YoY growth—execution on scale is real.
₹618 Cr order backlog provides 5+ quarters of visibility.
₹52 Cr SAEL solar order positions company in high-growth ecosystem.
Penta automation + Bioconserve ZLD are strategic, sector-aligned.
PAT collapsed 89.6% QoQ to ₹0.5 Cr despite 80% revenue growth.
Finance/tax leakage of ₹2.6 Cr erases operating leverage entirely.
Prior call promised 'stronger bottom-line'—Q1 delivered collapse.
Margin recovery target (7–8% EBITDA in 1–2 years) lacks timeline.
Order realization delayed (SAEL 6–8 mo, trading 1–1.5 yr)—near-term profit nil.
Market down 43% from ATH; FII/DII at 0%—zero institutional conviction.
Profit quality break (PAT down 89.6% QoQ despite 80% revenue growth).
HighSuggests margin control failure or one-time charge not disclosed. Until reconciled, assumes worst: broken profit engine.
Finance/tax leakage unreconciled (₹2.6 Cr gap, 82% of operating profit).
HighManagement did not explain OPM-to-NPM gap on call. Erodes confidence in financial controls and cost structure.
Order realization delays (SAEL 6–8 mo, trading 1–1.5 yr).
HighBacklog is an asset only if realized. Delays or order cancellations derail FY27 10% revenue guidance and push profit recovery to FY28+.
Margin recovery unproven (7–8% EBITDA target in 1–2 years, no bridge).
HighCurrent OPM 2.5%, delivered NPM 0.4%. Target lacks FY specificity, phased milestones, or action levers. Aspirational only.
Penta & Bioconserve integration risk (nascent, synergies theoretical).
MediumPenta ₹25 Cr baseline, 25–30% growth claimed over 2–3 years. Profitability unproven. Synergies (automation across divisions) lack quantification.
Geopolitical & macro headwinds (Middle East, tariffs, supply chain).
MediumDefense/aerospace orders depend on stable geopolitics. Raw material cost (copper, steel) inflation partially absorbed; margin pass-through stalling.
Competitive intensity (textile machinery: VA Tech Wabag, Ion Exchange entrenched).
Medium₹201 Cr textile backlog faces pricing pressure. Moat and pricing power weak in core segments.
1 · Q2 OPM recovery—the profit bridge proof
If OPM recovers toward 4%+ in Q2, the ₹2.6 Cr Q1 gap may have been one-time (finance settlement, provision reversal). If it repeats, the margin break is structural. This is the critical number.
2 · SAEL delivery progress (6–8 month window from Q1 = late FY27/early FY28)
As SAEL moves toward commissioning, management should quantify revenue recognition phasing. If delivery slips, FY27 10% guidance is at risk and profit recovery delays.
3 · FY27 full-year margin guidance revision
Management must articulate a quantified bridge: FY27 target OPM%, FY27 target PAT, and actions driving margin (Penta synergies, capex ROI, cost reduction). Without this, the 7–8% EBITDA target in '1–2 years' is aspirational.
This quarter is a step-change in scale (₹125 Cr revenue, 80% YoY), not in execution quality. The ₹618 Cr order backlog is a genuine asset—but realization is 1–2 years out and profitability unproven. The market's day-1 sell-off of 4.5% was justified; profit collapse despite 80% growth is a red flag, not noise.
Stock is down 43% from its all-time high but holding above 52-week lows (₹66.41). FII/DII ownership is at 0%, suggesting zero institutional conviction. The promoter at 72.41% is holding steady, signaling no insider distress, but also no insider buying to validate the turnaround story.
The number to track from here is reported OPM (not net profit, which is too noisy). If OPM stabilizes or improves toward 4% in Q2 FY27, the order backlog becomes a real catalyst. If it stays at 2.5%, the backlog is a burden—locked-in low-margin business that delays profitability recovery. Verdict: Hold. Scale is real, but profit quality must recover before the backlog can be banked as upside.